Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-TC4324 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Mononuclear Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Peripheral Blood |
Disease | Hepatitis C Virus |
Storage | Liquid Nitrogen |
Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
Human Hepatitis C Virus (HCV) Peripheral Blood Mononuclear Cells (PBMCs) are mainly derived from the peripheral blood of HCV-infected patients. HCV invades cells by binding to receptors such as CD81 and SR-BI on the surface of PBMCs through the envelope glycoprotein E1/E2, replicates at a low level in the cytoplasm, and forms a persistent infection reservoir. Mononuclear cells with round lymphocytes and monocytes; typically non-adherent, suspension growthHCV replication in PBMC can escape immune surveillance and lead to chronic inflammatory response. Chronic HCV infection can cause cirrhosis and hepatocellular carcinoma, and is associated with neurocognitive dysfunction, which may be related to the potential invasion of the virus on the central nervous system and PBMC-mediated immune activation. Persistent HCV infection reservoir in PBMCs; immune evasion through viral replication; associated with systemic effects like cirrhosis, hepatocellular carcinoma, and neurocognitive dysfunction through immune activation.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Hepatitis C Virus (HCV) Peripheral Blood Mononuclear Cells can be used to study the molecular mechanisms of virus evasion of immune clearance and establishment of persistent infection. They can also be used to screen small molecule inhibitors or immunomodulators targeting virus-host interactions, providing an experimental platform for the development of new HCV vaccines and therapeutic strategies for clearing viral reservoirs.